In vivo, SN-401 normalizes glucose tolerance by increasing insulin sensitivity and secretion in insulin-resistant T2D mouse models, while augmenting tissue glucose uptake, suppressing hepatic glucose production, inducing serum FGF21 levels, and reducing hepatic steatosis and hepatocyte damage (ballooning) in obese T2D mice. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.